Reprogrammed Interchange LLC, a 10% owner of Vor Biopharma (VOR), sold 73,676 shares for $2.35 million on October 15-16, 2025, following a 123% stock surge over the past six months. This insider activity coincides with positive news for VOR, including its collaborator RemeGen's telitacicept Phase 3 study meeting endpoints for Sjögren’s disease, prompting Baird to upgrade the stock to Outperform with a $64 price target. However, the company also filed a preliminary prospectus for the potential resale of up to 50 million shares from warrant exercises, indicating potential future dilution.
Reprogrammed Interchange LLC, a 10% owner of Vor Biopharma (VOR), sold 73,676 shares for $2.35 million on October 15-16, 2025, with prices ranging from $30.45 to $32.77. This insider transaction occurred after VOR's stock experienced a substantial 123% surge over the preceding six months, indicating profit-taking following strong performance, though the entity retains 1,204,442 shares. Concurrently, VOR announced positive Phase 3 clinical trial results for telitacicept in primary Sjögren’s disease, where 71.8% of patients achieved clinically meaningful reduction in disease activity. This catalyst prompted Baird to upgrade VOR from Neutral to Outperform, significantly raising its price target from $20 to $64, reflecting strong confidence in the therapy's potential. Despite these positive developments, VOR filed a preliminary prospectus for the potential resale of up to 50,999,999 shares from warrant exercises, posing a significant risk of future share dilution. The stock also exhibits high volatility with a beta of 2.08, and analyst price targets vary widely from $8 to $64, underscoring market uncertainty regarding its long-term valuation.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
